Skip to main content

Advertisement

SpringerLink
Log in

Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the effects of weekly post-operative intravitreal methotrexate injections on eyes with grade C proliferative vitreoretinopathy (PVR) that underwent surgical repair.

Methods

Retrospective case–control study of 16 eyes with retinal detachment and grade C PVR. Seven eyes received weekly intravitreal MTX injections post-operatively as an adjunct and 9 eyes served as the control. The main outcome measure was the retinal re-attachment rate.

Results

In the MTX group, 86% (6/7) of eyes had a complete retinal re-attachment at the end of the follow-up period. In contrast in the no MTX group, only 22.2% (2/9) of eyes had a complete retinal re-attachment (p = 0.0406). The patients in the MTX group received a mean of 6 injections (range 4–8). There were no cases of corneal epitheliopathy.

Conclusions

Serial intravitreal MTX as an adjunct to surgical repair holds promise for the management of PVR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Charteris DG, Sethi CS, Lewis GP, Fisher SK (2002) Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond) 16:369–374. https://doi.org/10.1038/sj.eye.6700194

    Article  CAS  Google Scholar 

  2. Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S (2016) Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res 51:125–155. https://doi.org/10.1016/j.preteyeres.2015.07.005

    Article  PubMed  Google Scholar 

  3. Pastor JC, de la Rua ER, Martin F (2002) Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 21:127–144. https://doi.org/10.1016/s1350-9462(01)00023-4

    Article  PubMed  Google Scholar 

  4. Banerjee PJ, Quartilho A, Bunce C, Xing W, Zvobgo TM, Harris N, Charteris DG (2017) Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmology 124:757–767. https://doi.org/10.1016/j.ophtha.2017.01.021

    Article  PubMed  Google Scholar 

  5. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM (1991) An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 112:159–165. https://doi.org/10.1016/s0002-9394(14)76695-4

    Article  CAS  PubMed  Google Scholar 

  6. Wiedemann P, Hilgers RD, Bauer P, Heimann K (1998) Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 126:550–559. https://doi.org/10.1016/s0002-9394(98)00115-9

    Article  CAS  PubMed  Google Scholar 

  7. Acar N, Kapran Z, Altan T, Unver YB, Pasaoglu E (2010) Pars planavitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy. Jpn J Ophthalmol 54:331–337. https://doi.org/10.1007/s10384-010-0807-z

    Article  PubMed  Google Scholar 

  8. Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C, Group PVRS (2004) A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 111:2240–2245. https://doi.org/10.1016/j.ophtha.2004.05.036

    Article  PubMed  Google Scholar 

  9. Schiff WM, Hwang JC, Ober MD, Olson JL, Dhrami-Gavazi E, Barile GR, Chang S, Mandava N (2007) Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol 125:1161–1167. https://doi.org/10.1001/archopht.125.9.1161

    Article  CAS  PubMed  Google Scholar 

  10. Williams RG, Chang S, Comaratta MR, Simoni G (1996) Does the presence of heparin and dexamethasone in the vitrectomyinfusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 234:496–503. https://doi.org/10.1007/BF00184858

    Article  CAS  PubMed  Google Scholar 

  11. Ando N, Sen HA, Berkowitz BA, Wilson CA, de Juan E Jr (1994) Localization and quantitation of blood-retinal barrier breakdown in experimental proliferative vitreoretinopathy. Arch Ophthalmol 112:117–122. https://doi.org/10.1001/archopht.1994.01090130127029

    Article  CAS  PubMed  Google Scholar 

  12. Rubsamen PE, Cousins SW (1997) Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina 17:44–50. https://doi.org/10.1097/00006982-199701000-00009

    Article  CAS  PubMed  Google Scholar 

  13. Kuo HK, Chen YH, Wu PC, Kuo YH (2015) The effects of Ozurdex(R) (dexamethasone intravitreal implant) on experimental proliferative vitreoretinopathy. Ophthalmologica 233:198–203. https://doi.org/10.1159/000371901

    Article  CAS  PubMed  Google Scholar 

  14. Visentin M, Zhao R, Goldman ID (2012) The antifolates. Hematol Oncol Clin North Am 26(629–648):ix. https://doi.org/10.1016/j.hoc.2012.02.002

    Article  Google Scholar 

  15. Brown PM, Pratt AG, Isaacs JD (2016) Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12:731–742. https://doi.org/10.1038/nrrheum.2016.175

    Article  CAS  PubMed  Google Scholar 

  16. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL (2009) Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 116:797–801. https://doi.org/10.1016/j.ophtha.2008.10.033

    Article  PubMed  Google Scholar 

  17. Kvopka M, Lake SR, Smith JR (2020) Intraocular chemotherapy for vitreoretinal lymphoma: a review. Clin Exp Ophthalmol 48:240–248. https://doi.org/10.1111/ceo.13668

    Article  PubMed  Google Scholar 

  18. Velez G, Yuan P, Sung C, Tansey G, Reed GF, Chan CC, Nussenblatt RB, Robinson MR (2001) Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 119:1518–1524. https://doi.org/10.1001/archopht.119.10.1518

    Article  CAS  PubMed  Google Scholar 

  19. Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J (2008) Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 92:383–388. https://doi.org/10.1136/bjo.2007.127928

    Article  CAS  PubMed  Google Scholar 

  20. Hardwig PW, Pulido JS, Bakri SJ (2008) The safety of intraocular methotrexate in silicone-filled eyes. Retina 28:1082–1086. https://doi.org/10.1097/IAE.0b013e3181754231

    Article  PubMed  Google Scholar 

  21. Amarnani D, Machuca-Parra AI, Wong LL, Marko CK, Stefater JA, Stryjewski TP, Eliott D, Arboleda-Velasquez JF, Kim LA (2017) Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 58:3940–3949. https://doi.org/10.1167/iovs.16-20912

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. GhasemiFalavarjani K, Modarres M, Hadavandkhani A, KarimiMoghaddam A (2015) Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy. Eye (Lond) 29:1199–1203. https://doi.org/10.1038/eye.2015.114

    Article  CAS  Google Scholar 

  23. Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD (2016) Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol 10:1811–1817. https://doi.org/10.2147/OPTH.S111893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Benner JD, Dao D, Butler JW, Hamill KI (2019) Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy. BMJ Open Ophthalmol 4:e000293. https://doi.org/10.1136/bmjophth-2019-000293

    Article  PubMed  PubMed Central  Google Scholar 

  25. Nourinia R, Borna F, Rahimi A, JabbarpoorBonyadi MH, Amizadeh Y, Daneshtalab A, Kheiri B, Ahmadieh H (2019) Repeated injection of methotrexate into silicone oil-filled eyes for grade C proliferative vitreoretinopathy: a pilot study. Ophthalmologica 242:113–117. https://doi.org/10.1159/000500271

    Article  CAS  PubMed  Google Scholar 

  26. Falavarjani KG, Hadavandkhani A, Parvaresh MM, Modarres M, Naseripour M, Alemzadeh SA (2020) Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy. Ocul Immunol Inflamm 28:513–516. https://doi.org/10.1080/09273948.2019.1597894

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oftalmologos Contreras, Lima, Peru

    José A. Roca, Analí Yon-Mendoza & Nathaly Huamán

  2. Asociados de Macula Vitreo Y Retina de Costa Rica Primer Piso Torre Mercedes Paseo Colón, San José, Costa Rica

    Lihteh Wu

  3. Illinois Eye and Ear Infirmary, University of Illinois School of Medicine, Chicago, IL, USA

    Lihteh Wu

Authors
  1. José A. Roca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Analí Yon-Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nathaly Huamán
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lihteh Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lihteh Wu.

Ethics declarations

Ethical approval

IRB approval was obtained from the Clinica Ricardo Palma IRB, Lima, Perú. Individual informed consent was obtained for the surgical treatment of the disease and the off-label use of intravitreal MTX. The study and data collection were performed in adherence to the tenets of the Declaration of Helsinki.

Conflict of interest

Dr. Wu has received lecture fees from Bayer and Quantel Medical. Drs Roca, Yon-Mendoza, and Huaman declare that they do not have any financial interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roca, J.A., Yon-Mendoza, A., Huamán, N. et al. Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 259, 2913–2917 (2021). https://doi.org/10.1007/s00417-021-05206-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-021-05206-z

Keywords

Search

Navigation